-

12:13:09 PM

LNTH Stock News

LNTH - Lantheus Holdings Inc

05/26/22 8:00 AM

Nasdaq : LNTH

Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow

RHEA-AI

negative

05/16/22 4:30 PM

Nasdaq : LNTH

Lantheus Hosts Inaugural Investor Day

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), will host its Inaugural Investor Day at the Nasdaq MarketSite on Tuesday, May 17,

RHEA-AI

neutral

05/16/22 8:00 AM

Nasdaq : LNTH

Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting

Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated

RHEA-AI

neutral

05/13/22 8:00 AM

Nasdaq : LNTH

clinical trial

Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients

Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider

RHEA-AI

neutral

05/11/22 8:00 AM

Nasdaq : LNTH

Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer

Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider

RHEA-AI

neutral

05/10/22 8:30 AM

Nasdaq : LNTH

conferences

Lantheus to Present at the UBS Global Healthcare Conference

Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow

RHEA-AI

neutral

04/29/22 7:07 AM

Nasdaq : LNTH

earnings

Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results

Worldwide revenue of $208.9 million for the first quarter 2022, representing an increase of 125.8% from the prior year period GAAP net income of $43.0 million for the first quarter 2022, compared to GAAP net income of $9.0 million in the prior year period GAAP fully diluted net income of $0.61 for

RHEA-AI

neutral

04/15/22 8:30 AM

Nasdaq : LNTH

conferencesearnings

Lantheus Holdings to Host First Quarter 2022 Earnings Conference Call and Webcast on April 29, 2022 at 8:00 a.m. Eastern Time

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Friday, April 29, 2022, to discuss its financial and operating results for the first quarter of

RHEA-AI

neutral

04/04/22 8:00 AM

Nasdaq : LNTH

management

Lantheus Appoints Jean-Claude Provost, MD as Interim Chief Medical Officer

Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow

RHEA-AI

very positive

03/29/22 8:00 AM

Nasdaq : LNTH

clinical trial

Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development

Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH),

RHEA-AI

very positive

1 2 3 4 5 6 7 Next

LNTH Data

IndustrySurgical and Medical Instrument Manufacturing
Websiteinvestor.lantheus.com
CeoMary Heino
Security nameLantheus Holdings Inc
Issue typecs
SectorManufacturing
Sic code2835
Employees595
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
Address331 Treble Cove Rd
StateMassachusetts
CityNorth Billerica
Zip01862-2849
CountryUS
Phone19786718001

About Lantheus Holdings Inc

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow™ serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden.